Oncology Research

Cergentis supports oncology research in various ways.


Firstly, the TLA technology provides the unique opportunity to sequence complete genes and detect all single nucleotide variants and structural variants (including gene fusions) in cancer genes. 


Secondly, Cergentis' TLA analyses support the characterisation of transgenic models used in oncology research (see Genetic Engineering). 

  • "Thank you so much. Data about the structural changes in our patient are very clear. Really powerful technology!”

    Alfredo Brusco Ph.D.(Department of Medical Sciences, University of Turin, Italy)
  • "Unknown translocation partners that drive expression of oncogenes as consequence of cryptic or previous unidentified chromosomal rearrangements were identified in T-cell leukemia patients using Targeted Locus Amplification.”

    Jules Meijerink Ph.D.(Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands)
  • "Targeted Locus Amplification enables fast identification of new chromosomal rearrangements and genomic breakpoint sequences in human T-ALL and unravelled a higher complexity of chromosomal translocations of known T-ALL oncogenes as thus far appreciated.”

    Pieter van Vlierberghe Ph.D.(Center for Medical Genetics, Ghent University, Belgium)
  • "We conclude that TLA is an effective method for the reliable detection of sequence mutations and structural variations that are relevant for disease prognosis in pediatric leukemia.”

    Roland Kuiper Ph.D.(Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands)
© 2012-2018 Cergentis B.V. All rights reserved.
For Research Use Only.Not for use in diagnostic procedures.
We use cookies for website analysis and marketing. By visiting and using our website you accept these cookies.